Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Exclusion Criteria

• •Treatment of CLL with chemotherapy, monoclonal antibody or radiotherapy within 60 days prior to entering the study. Acute toxicities from prior therapy must have resolved to Grade ≤ 1.
• •Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
• •Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD)
• •Active secondary malignancy or history of other malignancy within the last five years
• •Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral hepatitis (A, B or C).
• •Patients who are contraindicated for treatment with rituximab
• •Diagnosis of prolymphocytic leukemia, hairy cell leukemia, leukemic phase of non-Hodgkin's lymphoma, or other non-B-CLL B-cell malignancy;
• •T-CLL or other T-cell malignancy